MA33105B1 - Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase - Google Patents
Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestéraseInfo
- Publication number
- MA33105B1 MA33105B1 MA34150A MA34150A MA33105B1 MA 33105 B1 MA33105 B1 MA 33105B1 MA 34150 A MA34150 A MA 34150A MA 34150 A MA34150 A MA 34150A MA 33105 B1 MA33105 B1 MA 33105B1
- Authority
- MA
- Morocco
- Prior art keywords
- phenyl
- inhibitors
- phosphodiesterase
- pyridin
- benzoic acid
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 title 2
- 239000005711 Benzoic acid Substances 0.000 title 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 235000010233 benzoic acid Nutrition 0.000 title 1
- 125000001495 ethyl group Chemical class [H]C([H])([H])C([H])([H])* 0.000 title 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 1-PHENYL-2-PYRIDINYL Chemical class 0.000 abstract 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 1
- 150000001298 alcohols Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES INHIBITEURS DE L'ENZYME PHOSPHODIESTÉRASE 4 (PDE4). PLUS PARTICULIÈREMENT, L'INVENTION CONCERNE DES COMPOSÉS QUI SONT DÉRIVÉS D'ALCOOLS 1-PHÉNYL-2-PYRIDINYL ALKYLIQUES, DES PROCÉDÉS DE PRÉPARATION DESDITS COMPOSÉS, DES COMPOSITIONS LES COMPRENANT, LEURS COMBINAISONS ET LEURS UTILISATIONS THÉRAPEUTIQUES. DANS LA FORMULE (I), N REPRÉSENTE O OU 1; R1 ET R2 PEUVENT ÊTRE IDENTIQUES OU DIFFÉRENTS, ET SONT SÉLECTIONNÉS DANS LE GROUPE CONSTITUÉ PAR: - ALKYLE C1-C6 LINÉAIRE OU RAMIFIÉ; - OR3 OÙ R3 REPRÉSENTE ALKYLE C1-C6 ÉVENTUELLEMENT SUBSTITUÉ PAR UN OU PLUSIEURS GROUPES CYCLOALKYLES C3-C7; ET - HNSO2R4 OÙ R4 REPRÉSENTE ALKYLE C1-C4 ÉVENTUELLEMENT SUBSTITUÉ PAR UN OU PLUSIEURS ATOMES D'HALOGÈNE OU PAR UN GROUPE C1-C4, R1 ET/OU R2 REPRÉSENTANT HNSO2R4. LES AUTRES VARIABLES SONT TELLES QUE DÉFINIES DANS LES REVENDICATIONS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09001660A EP2216327A1 (fr) | 2009-02-06 | 2009-02-06 | Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase |
| PCT/EP2010/000676 WO2010089107A1 (fr) | 2009-02-06 | 2010-02-04 | Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33105B1 true MA33105B1 (fr) | 2012-03-01 |
Family
ID=40674203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34150A MA33105B1 (fr) | 2009-02-06 | 2010-02-04 | Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US8440834B2 (fr) |
| EP (2) | EP2216327A1 (fr) |
| JP (2) | JP5612610B2 (fr) |
| KR (1) | KR101337728B1 (fr) |
| CN (1) | CN102317262B (fr) |
| AR (1) | AR075243A1 (fr) |
| AU (1) | AU2010211274B2 (fr) |
| BR (1) | BRPI1005695A8 (fr) |
| CA (1) | CA2751494C (fr) |
| CL (1) | CL2011001876A1 (fr) |
| CO (1) | CO6400217A2 (fr) |
| CY (1) | CY1113764T1 (fr) |
| EA (1) | EA019113B1 (fr) |
| ES (1) | ES2395528T3 (fr) |
| GE (1) | GEP20135919B (fr) |
| HR (1) | HRP20121004T1 (fr) |
| IL (1) | IL214446A (fr) |
| JO (1) | JO2761B1 (fr) |
| MA (1) | MA33105B1 (fr) |
| ME (1) | ME02325B (fr) |
| MX (1) | MX2011007857A (fr) |
| MY (1) | MY152048A (fr) |
| NZ (1) | NZ594413A (fr) |
| PE (1) | PE20120055A1 (fr) |
| PL (1) | PL2393782T3 (fr) |
| PT (1) | PT2393782E (fr) |
| RS (1) | RS52605B (fr) |
| SG (1) | SG173208A1 (fr) |
| SI (1) | SI2393782T1 (fr) |
| TN (1) | TN2011000346A1 (fr) |
| TW (1) | TWI459945B (fr) |
| UA (1) | UA102574C2 (fr) |
| WO (1) | WO2010089107A1 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2022783A1 (fr) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase |
| EP2216327A1 (fr) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase |
| NO2600830T3 (fr) | 2010-08-03 | 2018-07-21 | ||
| KR101803121B1 (ko) * | 2010-08-03 | 2017-11-29 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포디에스테라제 억제제를 포함하는 약학적 제제 |
| WO2012168226A1 (fr) * | 2011-06-06 | 2012-12-13 | Chiesi Farmaceutici S.P.A. | Dérivés d'alcools 1-phényl-2-pyridinyl alkyliques utilisés en tant qu'inhibiteurs de phosphodiestérase |
| EP2760838B1 (fr) | 2011-09-26 | 2017-05-10 | Chiesi Farmaceutici S.p.A. | Dérivés de 1-phényl-2-pyridinyl alkyl alcool en tant qu'inhibiteurs du phosphodiestérase |
| BR112014009471A2 (pt) | 2011-10-21 | 2017-04-18 | Chiesi Farm Spa | compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit |
| WO2013087749A1 (fr) * | 2011-12-16 | 2013-06-20 | Chiesi Farmaceutici S.P.A. | Potentialisation induite par des inhibiteurs de pdea dans le traitement de la leucémie |
| IN2014DN10239A (fr) * | 2012-06-04 | 2015-08-07 | Chiesi Farma Spa | |
| KR20150092173A (ko) * | 2012-12-05 | 2015-08-12 | 키에시 파르마슈티시 엣스. 피. 에이. | Pde4-억제제로서 페닐에틸피리딘 유도체 |
| CN104822669A (zh) | 2012-12-05 | 2015-08-05 | 奇斯药制品公司 | 作为pde-4抑制剂的苯基乙基吡啶衍生物 |
| EP2928869B1 (fr) * | 2012-12-05 | 2019-02-20 | Chiesi Farmaceutici S.p.A. | Dérivés d'alcool 1-phényl-2-pyridinyl alkylique en tant qu'inhibiteurs de phosphodiestérase |
| CA2893622A1 (fr) | 2012-12-05 | 2014-06-12 | Chiesi Farmaceutici S.P.A. | Derives de phenylethylpyridine en tant qu'inhibiteurs de pde4 |
| US9427376B2 (en) | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| RS61558B1 (sr) | 2013-10-22 | 2021-04-29 | Chiesi Farm Spa | Kristalni oblik pde4 inhibitora |
| US9145409B2 (en) | 2013-12-05 | 2015-09-29 | Chiesi Farmaceutici S.P.A | Benzhydryl derivatives |
| HK1225385A1 (zh) | 2013-12-05 | 2017-09-08 | 奇斯药制品公司 | 用於治疗呼吸病的杂芳基衍生物 |
| EP3152202B1 (fr) * | 2014-06-04 | 2018-11-28 | Chiesi Farmaceutici S.p.A. | Dérivés de 3,5-dichloro,4-(3,4-(cyclo-)alcoxyphényl)--2-carbonyloxy)éthyl)pyridine utilisés comme inhibiteurs de pde-4 et antagonistes des recepteures muscarinic m3 |
| EP3152203A1 (fr) * | 2014-06-04 | 2017-04-12 | Chiesi Farmaceutici S.p.A. | Dérivés de 3,5-dichloro,4-(3,4-(cyclo-)alcoxyphényl)-2-carbonyloxy)éthyl)pyridine utilisés comme inhibiteurs de pde-4 |
| US9763924B2 (en) * | 2014-06-05 | 2017-09-19 | Chiesi Farmaceutici S.P.A. | Aminoester derivatives |
| US9326976B2 (en) * | 2014-06-05 | 2016-05-03 | Chiesi Farmaceutici S.P.A. | Carbamate derivatives |
| WO2017089347A1 (fr) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf |
| EP3487501A1 (fr) * | 2016-07-20 | 2019-05-29 | Allergan, Inc. | Méthodes, compositions et composés pour le traitement d'états pathologiques dermatologiques et oculaires |
| MA51413A (fr) * | 2017-12-28 | 2021-04-28 | Chiesi Farm Spa | Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique |
| BR112021001402A2 (pt) | 2018-07-27 | 2021-04-27 | Chiesi Farmaceutici S.P.A. | novas partículas carreadoras para formulações de pó seco para inalação |
| CN115466169B (zh) * | 2021-06-10 | 2024-03-26 | 中国医学科学院药物研究所 | 取代邻苯二酚醚类化合物及其制备方法和应用 |
| CN118475343A (zh) | 2021-12-21 | 2024-08-09 | 凯西制药公司 | 填充在具有改善的耐湿性的吸入器中的干粉制剂 |
| WO2023208982A1 (fr) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Forme cristalline d'un inhibiteur de pde4 |
| WO2024027901A1 (fr) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4 |
| CA3268102A1 (fr) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4 |
| KR20250069949A (ko) | 2022-09-22 | 2025-05-20 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포다이에스테라제-4 억제제의 투여를 위한 캡슐 흡입기 |
| CA3268243A1 (fr) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4 |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
| WO2025149100A2 (fr) * | 2025-04-29 | 2025-07-17 | 北京泰德制药股份有限公司 | Composition pharmaceutique contenant un composé a inhibiteur de pde4 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263495B (fr) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| CN1046939C (zh) * | 1993-07-02 | 1999-12-01 | 比克·古尔顿·劳姆贝尔格化学公司 | 氟烷氧基取代的苯甲酰胺类及其制备方法和应用 |
| GB9412573D0 (en) * | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| EP2044023B1 (fr) | 2006-07-14 | 2011-01-19 | CHIESI FARMACEUTICI S.p.A. | Derivés d'alcools de 1-phényl-2-pyridynyl alkylène en tant qu'inhibiteurs de phosphodiestérase |
| EP2022783A1 (fr) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase |
| EP2070913A1 (fr) | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Dérivés d'ester en tant qu'inhibiteurs de la phosphodiestérase |
| EP2110375A1 (fr) | 2008-04-14 | 2009-10-21 | CHIESI FARMACEUTICI S.p.A. | Inhibiteurs de la phosphodiestérase de type 4 appartenant à la classe tertiaire d'amine |
| EP2216327A1 (fr) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase |
| NO2600830T3 (fr) | 2010-08-03 | 2018-07-21 | ||
| KR101803121B1 (ko) | 2010-08-03 | 2017-11-29 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포디에스테라제 억제제를 포함하는 약학적 제제 |
| WO2012168226A1 (fr) | 2011-06-06 | 2012-12-13 | Chiesi Farmaceutici S.P.A. | Dérivés d'alcools 1-phényl-2-pyridinyl alkyliques utilisés en tant qu'inhibiteurs de phosphodiestérase |
| EP2760838B1 (fr) | 2011-09-26 | 2017-05-10 | Chiesi Farmaceutici S.p.A. | Dérivés de 1-phényl-2-pyridinyl alkyl alcool en tant qu'inhibiteurs du phosphodiestérase |
| BR112014009471A2 (pt) | 2011-10-21 | 2017-04-18 | Chiesi Farm Spa | compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit |
| IN2014DN10239A (fr) | 2012-06-04 | 2015-08-07 | Chiesi Farma Spa | |
| EP2928869B1 (fr) | 2012-12-05 | 2019-02-20 | Chiesi Farmaceutici S.p.A. | Dérivés d'alcool 1-phényl-2-pyridinyl alkylique en tant qu'inhibiteurs de phosphodiestérase |
-
2009
- 2009-02-06 EP EP09001660A patent/EP2216327A1/fr not_active Withdrawn
-
2010
- 2010-02-03 JO JO201033A patent/JO2761B1/en active
- 2010-02-04 WO PCT/EP2010/000676 patent/WO2010089107A1/fr not_active Ceased
- 2010-02-04 CA CA2751494A patent/CA2751494C/fr active Active
- 2010-02-04 UA UAA201108827A patent/UA102574C2/ru unknown
- 2010-02-04 JP JP2011548600A patent/JP5612610B2/ja active Active
- 2010-02-04 ME MEP-2016-19A patent/ME02325B/me unknown
- 2010-02-04 SG SG2011056165A patent/SG173208A1/en unknown
- 2010-02-04 GE GEAP201012324A patent/GEP20135919B/en unknown
- 2010-02-04 PT PT107047466T patent/PT2393782E/pt unknown
- 2010-02-04 PL PL10704746T patent/PL2393782T3/pl unknown
- 2010-02-04 KR KR1020117016842A patent/KR101337728B1/ko active Active
- 2010-02-04 NZ NZ594413A patent/NZ594413A/xx unknown
- 2010-02-04 AR ARP100100311A patent/AR075243A1/es not_active Application Discontinuation
- 2010-02-04 CN CN201080006643.7A patent/CN102317262B/zh active Active
- 2010-02-04 TW TW099103291A patent/TWI459945B/zh active
- 2010-02-04 RS RS20120547A patent/RS52605B/sr unknown
- 2010-02-04 SI SI201030094T patent/SI2393782T1/sl unknown
- 2010-02-04 EP EP10704746A patent/EP2393782B1/fr active Active
- 2010-02-04 HR HRP20121004AT patent/HRP20121004T1/hr unknown
- 2010-02-04 EA EA201190099A patent/EA019113B1/ru unknown
- 2010-02-04 ES ES10704746T patent/ES2395528T3/es active Active
- 2010-02-04 BR BRPI1005695A patent/BRPI1005695A8/pt active IP Right Grant
- 2010-02-04 AU AU2010211274A patent/AU2010211274B2/en active Active
- 2010-02-04 MX MX2011007857A patent/MX2011007857A/es active IP Right Grant
- 2010-02-04 MA MA34150A patent/MA33105B1/fr unknown
- 2010-02-04 PE PE2011001441A patent/PE20120055A1/es active IP Right Grant
- 2010-02-04 MY MYPI2011003639 patent/MY152048A/en unknown
- 2010-02-05 US US12/700,926 patent/US8440834B2/en active Active
-
2011
- 2011-07-13 TN TN2011000346A patent/TN2011000346A1/fr unknown
- 2011-08-04 CL CL2011001876A patent/CL2011001876A1/es unknown
- 2011-08-04 CO CO11098671A patent/CO6400217A2/es not_active Application Discontinuation
- 2011-08-04 IL IL214446A patent/IL214446A/en active IP Right Grant
-
2012
- 2012-09-14 US US13/618,346 patent/US20130012487A1/en not_active Abandoned
- 2012-12-04 CY CY20121101183T patent/CY1113764T1/el unknown
-
2013
- 2013-06-28 US US13/930,304 patent/US8648204B2/en active Active
- 2013-12-17 US US14/108,731 patent/US8859778B2/en active Active
-
2014
- 2014-09-04 JP JP2014179895A patent/JP2015038079A/ja active Pending
- 2014-09-10 US US14/482,287 patent/US9056176B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33105B1 (fr) | Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase | |
| MA30784B1 (fr) | Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs. | |
| MA31919B1 (fr) | Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif | |
| MA29909B1 (fr) | Derives de pyridazine | |
| MA32150B1 (fr) | Inhibiteurs heterocycliques de la stearoyl-coa desaturase | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| CO2022014876A2 (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
| MA47447A (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MA29141B1 (fr) | Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases | |
| MA34359B1 (fr) | Dérivés de carbamate d'hexafluoroisopropyle, leur préparation et leur application thérapeutique | |
| MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
| MA45222B1 (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA27559A1 (fr) | Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA47301B1 (fr) | Inhibiteurs sélectifs de jak1 | |
| MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
| MA35012B1 (fr) | Composition phytosanitaire comprenant des huiles essentielles renforçant l'activité anti-fongique | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| EP4249070A3 (fr) | Dérivés hétéroaryle bicycliques utilisés en tant qu'inhibiteurs de l'ectonucléotide pyrophosphatase/phosphodiestérase 1 | |
| MA34308B1 (fr) | Triazolopyridines substituées | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA32929B1 (fr) | Lactames en tant qu'inhibiteurs de bêta-sécrétase | |
| MA43960B1 (fr) | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 | |
| MA34917B1 (fr) | Dérivés substitués de l'acide 3-hétéroaroylamino-propionique et leur utilisation comme composés pharmaceutiques |